Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US
Ermer T, Canavan ME, Maduka RC, Li AX, Salazar MC, Kaminski MF, Pichert MD, Zhan PL, Mase V, Kluger H, Boffa DJ (2022)
Publication Type: Journal article
Publication year: 2022
Journal
Book Volume: 5
Journal Issue: 6
DOI: 10.1001/jamanetworkopen.2022.19535
Abstract
IMPORTANCE Clinical trials and compassionate use agreements provide selected patients with access to potentially life-saving treatments before approval by the Food and Drug Administration (FDA). Approval from the FDA decreases a number of access barriers; however, it is unknown whether FDA approval is associated with increases in the equitable use of novel therapies and reductions in disparities in use among patients with cancer in the US.
Involved external institutions
United States (USA) (US)How to cite
APA:
Ermer, T., Canavan, M.E., Maduka, R.C., Li, A.X., Salazar, M.C., Kaminski, M.F.,... Boffa, D.J. (2022). Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US. JAMA Network Open, 5(6). https://dx.doi.org/10.1001/jamanetworkopen.2022.19535
MLA:
Ermer, Theresa, et al. "Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US." JAMA Network Open 5.6 (2022).
BibTeX: Download